About Obalon Therptcs (NASDAQ:OBLN)
Obalon Therapeutics, Inc. is a United States-based commercial-stage medical device company focused on developing and commercializing medical devices to treat obese and overweight people by facilitating weight loss. The Company's product, Obalon balloon system, is a swallowable, gas-filled intragastric balloon designed to provide weight loss in obese patients. The Obalon balloon system is intended to be used as an adjunct to a moderate intensity diet and behavior modification program. All balloons must be removed six months after the first balloon is placed. The Obalon balloon system intends to provide patients and physicians with a reversible and repeatable weight loss solution in an outpatient setting, without altering patient anatomy or requiring surgery. The Company has received Premarket approval (PMA) for its Obalon balloon system based on the results of its United States pivotal clinical trial, referred to as the SMART trial.
Industry, Sector and Symbol
Industry Medical Devices & Implants
Trailing P/E RatioN/A
Forward P/E RatioN/A
Sales & Book Value
Annual Sales$3.39 million
Price / Sales38.58
Price / CashN/A
Book Value$3.83 per share
Price / Book1.96
Return on Equity-59.77%
Return on Assets-47.02%
Obalon Therptcs (NASDAQ:OBLN) Frequently Asked Questions
What is Obalon Therptcs' stock symbol?
Obalon Therptcs trades on the NASDAQ under the ticker symbol "OBLN."
How were Obalon Therptcs' earnings last quarter?
Obalon Therptcs (NASDAQ:OBLN) released its earnings results on Friday, November, 3rd. The company reported ($0.55) EPS for the quarter, missing the Zacks' consensus estimate of ($0.43) by $0.12. The firm had revenue of $2.79 million for the quarter, compared to analyst estimates of $2.95 million. Obalon Therptcs had a negative return on equity of 59.77% and a negative net margin of 459.54%. View Obalon Therptcs' Earnings History.
When will Obalon Therptcs make its next earnings announcement?
Where is Obalon Therptcs' stock going? Where will Obalon Therptcs' stock price be in 2017?
3 Wall Street analysts have issued 1 year price objectives for Obalon Therptcs' shares. Their forecasts range from $4.00 to $17.00. On average, they expect Obalon Therptcs' share price to reach $12.00 in the next twelve months. View Analyst Ratings for Obalon Therptcs.
What are Wall Street analysts saying about Obalon Therptcs stock?
Here are some recent quotes from research analysts about Obalon Therptcs stock:
- 1. BTIG Research analysts commented, "Agreements, Navigation, and Market Growth We hosted CEO Andy Rasdal and CFO Bill Plovanic for a series of investor meetings. Overall, management remained upbeat about the long-term opportunity, underpinned by the recently announced agreement with Sono Bello (Private) and potential incremental revenue stream afforded by the yet-to-be approved navigation system. Sono Bello adds a sizable aesthetic practice to existing customer base. OBLN’s agreement with Sono Bello is important for a variety of reasons. First, the agreement provides a significant boost to the account base (40+ locations, 100+ physicians) and adds a focus from Sono Bello to offer a novel weight loss solution. Second, the agreement will help with other potential plastic surgeon customers who may look to Sono Bello for indications of patient interest. We expect Sono Bello to roll OBLN out in stages as it figures out how best to offer balloons and also benefit its own liposuction practice. Navigation, while still not FDA cleared, removes a barrier to entry. Mgmt. provided incremental details on the navigation system including expectations to be substantially less expensive than X-Ray. We believe the Navigation system may be approved in 1H18 as PMA supplements usually take approximately 6 months and it has been submitted." (11/16/2017)
- 2. According to Zacks Investment Research, "Obalon Therapeutics, Inc. is a medical device company. It focused on developing and commercializing medical devices to treat obese and overweight. The company's product consists of Obalon balloon system, the first swallowable, gas-filled intragastric balloon designed to provide progressive and sustained weight loss in obese patients. Obalon Therapeutics, Inc. is based in San Diego, California. " (11/16/2017)
- 3. Northland Securities analysts commented, "We are initiating coverage of Obalon Therapeutics with an Underperform rating / $6 PT. We are concerned that forward estimates are too high, the science is unclear, the logistical issues of 3- intragastric balloon (IGB) procedures remain, and finally, ponying up $8,000 or so in a cash-pay procedure for a 15 lb. weight loss makes this product more suitable for a wealthy, event-driven" motivated patient, therefore making the realistic TAM quite small." (6/21/2017)
- 4. Canaccord Genuity analysts commented, "We reiterate our BUY rating following marketing meetings with management. We recently hosted two days of upbeat investor meetings with Obalon CEO Andy Rasdal as well as CFO Bill Plovanic. We came away from those meetings with a clearer understanding of investor sentiment as well as early commercial traction in the US launch." (5/18/2017)
Who are some of Obalon Therptcs' key competitors?
Who are Obalon Therptcs' key executives?
Obalon Therptcs' management team includes the folowing people:
- Kim P Kamdar, Chairman of the Board (Age 49)
- Andrew Rasdal, President, Chief Executive Officer, Director (Age 58)
- William J. Plovanic, Chief Financial Officer (Age 47)
- Kelly Huang Ph.D., Chief Operating Officer (Age 48)
- Nooshin Hussainy, Vice President - Finance (Age 58)
- Steve Johnson, Vice President - Operations (Age 58)
- Matthew Norwood, Vice President of Sales (Age 41)
- Lisa Metzner, Vice President of Marketing (Age 47)
- Amy VandenBerg, Vice President - Regulatory and Clinical Affairs (Age 41)
- Donald Young, Vice President of Quality Assurance (Age 58)
When did Obalon Therptcs IPO?
(OBLN) raised $75 million in an IPO on Thursday, October 6th 2016. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. UBS Investment Bank, Canaccord Genuity and Stifel served as the underwriters for the IPO and BTIG was co-manager.
Who owns Obalon Therptcs stock?
Obalon Therptcs' stock is owned by many different of retail and institutional investors. Top institutional investors include C WorldWide Group Holding A S (1.58%), Granite Investment Partners LLC (0.62%), Wasatch Advisors Inc. (0.52%) and Emerald Mutual Fund Advisers Trust (0.38%). Company insiders that own Obalon Therptcs stock include Kim P Kamdar and Matthew Norwood. View Institutional Ownership Trends for Obalon Therptcs.
Who sold Obalon Therptcs stock? Who is selling Obalon Therptcs stock?
Who bought Obalon Therptcs stock? Who is buying Obalon Therptcs stock?
Obalon Therptcs' stock was bought by a variety of institutional investors in the last quarter, including Granite Investment Partners LLC, C WorldWide Group Holding A S and Emerald Mutual Fund Advisers Trust. Company insiders that have bought Obalon Therptcs stock in the last two years include Kim P Kamdar and Matthew Norwood. View Insider Buying and Selling for Obalon Therptcs.
How do I buy Obalon Therptcs stock?
Shares of Obalon Therptcs can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Obalon Therptcs' stock price today?
One share of Obalon Therptcs stock can currently be purchased for approximately $7.50.
How big of a company is Obalon Therptcs?
Obalon Therptcs has a market capitalization of $130.81 million and generates $3.39 million in revenue each year. The company earns $-20,460,000.00 in net income (profit) each year or ($1.93) on an earnings per share basis. Obalon Therptcs employs 11 workers across the globe.
How can I contact Obalon Therptcs?
Obalon Therptcs' mailing address is 5421 Avenida Encinas Ste F, CARLSBAD, CA 92008-4410, United States. The company can be reached via phone at +1-858-4802400 or via email at [email protected]
MarketBeat Community Rating for Obalon Therptcs (OBLN)MarketBeat's community ratings are surveys of what our community members think about Obalon Therptcs and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Obalon Therptcs (NASDAQ:OBLN) Analysts' Consensus Rating (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus analyst ratings for company stocks using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Today||30 Days Ago||90 Days Ago||180 Days Ago|
|Consensus Rating: ||Buy||Buy||Buy||Buy|
|Consensus Rating Score: ||2.50||2.50||2.50||3.00|
|Ratings Breakdown: ||1 Sell Rating(s)|
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
|1 Sell Rating(s)|
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
|1 Sell Rating(s)|
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
|0 Sell Rating(s)|
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
|Consensus Price Target: ||$13.50||$13.50||$15.25||$18.33|
|Price Target Upside: ||73.52% upside||50.67% upside||84.18% upside||80.62% upside|
Obalon Therptcs (NASDAQ:OBLN) Consensus Price Target History
Obalon Therptcs (NASDAQ:OBLN) Analyst Ratings History
(Data available from 12/13/2015 forward)
Obalon Therptcs (NASDAQ:OBLN) Earnings History and Estimates Chart
Obalon Therptcs (NASDAQ OBLN) Earnings History by Quarter
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|11/3/2017||Q3 2017||($0.43)||($0.55)||$2.95 million||$2.79 million||View||N/A|
|8/2/2017||Q2 2017||($0.43)||($0.46)||$1.77 million||$1.96 million||View||Listen|
|5/10/2017||Q1 2017||($0.33)||($0.47)||$1.60 million||$1.47 million||View||N/A|
|11/11/2016||Q3 2016||($0.32)||($5.46)||$0.70 million||$0.77 million||View||Listen|
Obalon Therptcs (NASDAQ:OBLN) Earnings Estimates
Current Year EPS Consensus Estimate: $-1.96 EPS
Next Year EPS Consensus Estimate: $-1.68 EPS
Dividend History for Obalon Therptcs (NASDAQ:OBLN)
No dividend announcements for this company have been tracked by MarketBeat.com
Obalon Therptcs (NASDAQ OBLN) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 16.40%
Institutional Ownership Percentage: 44.05%
Obalon Therptcs (NASDAQ OBLN) Insider Trades by Quarter
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|10/12/2016||Kim P Kamdar||Director||Buy||13,400||$15.00||$201,000.00|| |
|10/12/2016||Matthew Norwood||VP||Buy||1,000||$15.00||$15,000.00|| |
Obalon Therptcs (NASDAQ OBLN) News Headlines
|Zacks: Analysts Anticipate Obalon Therptcs (OBLN) Will Announce Quarterly Sales of $3.52 Million|
www.americanbankingnews.com - December 11 at 8:14 AM
|Analyzing Obalon Therptcs (OBLN) & OrthoPediatrics (KIDS)|
www.americanbankingnews.com - December 11 at 1:26 AM
|Zacks: Analysts Expect Obalon Therptcs (OBLN) to Announce -$0.48 EPS|
www.americanbankingnews.com - December 9 at 7:16 PM
|Obalon Therptcs (OBLN) versus Its Rivals Critical Contrast|
www.americanbankingnews.com - December 6 at 1:28 AM
|Comparing Obalon Therptcs (OBLN) & Its Competitors|
www.americanbankingnews.com - December 4 at 8:00 AM
|Contrasting Obalon Therptcs (OBLN) & Its Rivals|
www.americanbankingnews.com - December 1 at 2:24 PM
|Head-To-Head Review: Obalon Therptcs (OBLN) versus Its Competitors|
www.americanbankingnews.com - November 28 at 7:56 AM
|Critical Survey: Endologix (ELGX) & Obalon Therptcs (OBLN)|
www.americanbankingnews.com - November 27 at 12:15 PM
|Obalon Therptcs (OBLN) Given Consensus Rating of "Hold" by Analysts|
www.americanbankingnews.com - November 27 at 4:10 AM
|$3.52 Million in Sales Expected for Obalon Therptcs (OBLN) This Quarter|
www.americanbankingnews.com - November 23 at 2:46 AM
|ETFs with exposure to Obalon Therapeutics, Inc. : November 21, 2017|
finance.yahoo.com - November 22 at 6:21 AM
|Obalon Therptcs (OBLN) versus The Competition Financial Review|
www.americanbankingnews.com - November 22 at 5:26 AM
|Zacks: Analysts Anticipate Obalon Therptcs (OBLN) to Post -$0.48 EPS|
www.americanbankingnews.com - November 21 at 9:26 PM
|Are You Backing The Right Horse With Obalon Therapeutics Inc (OBLN)?|
finance.yahoo.com - November 21 at 8:55 AM
|Obalon Therptcs (OBLN) versus The Competition Critical Analysis|
www.americanbankingnews.com - November 20 at 5:24 PM
|Obalon Therptcs (OBLN) and The Competition Head-To-Head Comparison|
www.americanbankingnews.com - November 18 at 1:32 PM
|Contrasting Obalon Therptcs (OBLN) and Its Peers|
www.americanbankingnews.com - November 17 at 5:22 AM
|Obalon Therptcs (OBLN) Receives Buy Rating from BTIG Research|
www.americanbankingnews.com - November 16 at 9:42 AM
|Obalon Therptcs (OBLN) Upgraded by Zacks Investment Research to Hold|
www.americanbankingnews.com - November 16 at 6:32 AM
|Obalon Therptcs (OBLN) & Its Peers Head to Head Analysis|
www.americanbankingnews.com - November 13 at 5:14 AM
|UBS AG Cuts OBALON THERPTCS (OBLN) Price Target to $16.00|
www.americanbankingnews.com - November 12 at 8:39 AM
|ETFs with exposure to Obalon Therapeutics, Inc. : November 8, 2017|
finance.yahoo.com - November 9 at 7:59 AM
|Contrasting Obalon Therptcs (OBLN) and Its Competitors|
www.americanbankingnews.com - November 7 at 5:17 PM
|Obalon Therapeutics, Inc. :OBLN-US: Earnings Analysis: Q3, 2017 By the Numbers : November 7, 2017|
finance.yahoo.com - November 7 at 4:38 PM
|Obalon Announces Upcoming Conference Presentations|
finance.yahoo.com - November 7 at 8:05 AM
|Obalon Therptcs (OBLN) PT Lowered to $15.00 at BTIG Research|
www.americanbankingnews.com - November 6 at 8:08 AM
|China Kanghui Holdings (KH) and Obalon Therptcs (OBLN) Head-To-Head Analysis|
www.americanbankingnews.com - November 6 at 7:24 AM
|Northland Securities Reaffirms Sell Rating for Obalon Therptcs (OBLN)|
www.americanbankingnews.com - November 5 at 1:34 PM
|Obalon Therapeutics, Inc. to Host Earnings Call|
finance.yahoo.com - November 4 at 8:19 AM
|Obalon Therptcs (OBLN) Issues Quarterly Earnings Results|
www.americanbankingnews.com - November 3 at 9:30 PM
|Obalon Therptcs (OBLN) Given Average Rating of "Hold" by Analysts|
www.americanbankingnews.com - November 2 at 3:50 AM
|Obalon Therptcs (OBLN) Set to Announce Quarterly Earnings on Friday|
www.americanbankingnews.com - October 28 at 10:38 AM
|Obalon Schedules Third Quarter 2017 Financial Results Conference Call for November 3, 2017 at 8:30 a.m. Eastern Time|
finance.yahoo.com - October 27 at 8:56 AM
|OBALON THERPTCS (OBLN) Expected to Announce Quarterly Sales of $2.95 Million|
www.americanbankingnews.com - October 15 at 5:32 AM
|Zacks: Analysts Anticipate Obalon Therptcs (OBLN) to Announce -$0.43 Earnings Per Share|
www.americanbankingnews.com - October 13 at 2:18 PM
|Obalon Therptcs (OBLN) Receives Average Rating of "Hold" from Analysts|
www.americanbankingnews.com - October 8 at 2:56 AM
|Financial Analysis: Second Sight Medical Products (EYES) vs. Obalon Therptcs (OBLN)|
www.americanbankingnews.com - October 1 at 12:18 PM
|Head to Head Analysis: Obalon Therptcs (OBLN) & Second Sight Medical Products (EYES)|
www.americanbankingnews.com - September 23 at 12:26 AM
|Obalon Therptcs (OBLN) Receives Average Recommendation of "Hold" from Analysts|
www.americanbankingnews.com - September 13 at 2:50 AM
|Kelly Huang, Ph.D., Joins Obalon Therapeutics, Inc. Executive Team|
finance.yahoo.com - September 8 at 6:39 AM
|OBALON THERPTCS (OBLN) and HeartWare International (HTWR) Critical Comparison|
www.americanbankingnews.com - September 4 at 4:08 PM
|Head to Head Survey: OBALON THERPTCS (OBLN) & Glaukos Corporation (GKOS)|
www.americanbankingnews.com - September 2 at 4:22 AM
|Critical Review: OBALON THERPTCS (OBLN) versus HeartWare International (HTWR)|
www.americanbankingnews.com - August 31 at 8:08 AM
|Obalon Therptcs (OBLN) and Trivascular Technologies (TRIV) Head to Head Comparison|
www.americanbankingnews.com - August 27 at 12:28 PM
|Analyzing Obalon Therptcs (OBLN) and St Jude Medical (STJ)|
www.americanbankingnews.com - August 24 at 12:20 AM
|Obalon Therptcs (OBLN) Expected to Post Quarterly Sales of $2.95 Million|
www.americanbankingnews.com - August 20 at 3:16 AM
|Analyzing HeartWare International (HTWR) & OBALON THERPTCS (OBLN)|
www.americanbankingnews.com - August 19 at 12:30 PM
|Obalon Therptcs (OBLN) Receives Consensus Rating of "Hold" from Analysts|
www.americanbankingnews.com - August 19 at 2:42 AM
|Obalon Therptcs (NASDAQ:OBLN) Issues Earnings Results|
www.americanbankingnews.com - August 3 at 4:34 PM
|Investor Network: Obalon Therapeutics, Inc. to Host Earnings Call|
finance.yahoo.com - August 3 at 6:32 AM
Obalon Therptcs (NASDAQ:OBLN) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Obalon Therptcs (NASDAQ:OBLN) Income Statement, Balance Sheet and Cash Flow Statement
Obalon Therptcs (NASDAQ OBLN) Stock Chart for Wednesday, December, 13, 2017